18F-FDG-PET and histopathology in 131I-lipiodol treatment for primary liver cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 4, 2009, Pages 445-452

  Risse, Jörn H ^a,b,d   Pauleit, Dirk ^a,c   Bender, Hans ^b,d   Rabe, Christian ^b   Fischer, Hans Peter ^b   Biersack, Hans Jürgen ^b   Bucerius, Jan ^b  

^a Radiology and Nuclear Medicine Institute   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c FORSCHUNGSZENTRUM JÜLICH   (Germany)

^d Roentgeninstitut Düsseldorf ^*  (Germany)

Author keywords

131I lipiodol; Computed tomography; FDG PET; Hepatocellular carcinoma; Histopathology; Iodine 131 lipiodol; Positron emission tomography; Selective internal radiation therapy; SIRT

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; IODINATED POPPYSEED OIL; IODINATED POPPYSEED OIL I 131; IODINE 131; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; FLUORINE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER GRADING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR VOLUME; LIVER TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SCINTISCANNING;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; IODIZED OIL; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 69249122934     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0560     Document Type: Article

References (24)

1. Lambert B, Van de Wiele C. Treatment of hepatocellular carcinoma by means of radiopharmaceuticals. Review. Eur J Nucl Med Mol Imaging 2005;32:980.
2. Risse JH, Rabe C, Pauleit D, et al. Therapy of hepatocellular carcinoma with iodine-131-lipiodol. Results in a large German cohort. Nuklearmedizin 2006;45:185.
3. Risse JH. Liver cancer. In: Oehr P, Biersack HJ, Coleman E (eds.): PET and PET-CT in Oncology. Berlin/Heidelberg/New York: Springer, 2004;203.
4. Yang SH, Suh KS, Lee HW, et al. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 2006;12:1655.
5. 18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg 2003;69:117.
6. Chen YK, Hsieh DS, Liao CS, et al. Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence. Anticancer Res 2005;25:4719.
7. Cheng MF, Wu YW, Tzen KY, et al. Whole-body F-18 FDGPET for hepatocellular carcinoma patients after interventional treatment. Neoplasma 2007;54:342.
8. Paudyal B, Oriuchi N, Paudyal P, et al. Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy. Oncol Rep 2007;18:1469.
9. Llovet JM, Fuster J, Bruix J, for the Barcelona-Clinic Liver Cancer Group. The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004;10:S115.
10. Risse JH, Grunwald F, Kersjes W, et al. Intra-arterial HCC therapywith I-131-lipiodol. Cancer Biother Radiopharm2000;15:65.
11. Talbot JN, Gutman F, Fartoux L, et al. PET=CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: Preliminary comparison with [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging 2006;33:1285.
12. 18F- fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. Oncology 2007;72(Suppl 1):104.
13. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003;44:213.
14. Seo S, Hatano E, Higashi T, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 2007;13:427.
15. Verhoef C, Valkema R, de Man RA, et al. Fluorine-18 FDG imaging in hepatocellular carcinoma using positron coincidence detection and single photon emission computed tomography. Liver 2002;22:51.
16. Keiding S, Hansen SB, Rasmussen HH, et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology 1998;28:700.
17. Iwata Y, Shiomi S, Sasaki N, et al. Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors. Ann Nucl Med 2000;14:121.
18. Lee JD, Yang WI, Park YN, et al. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake. J Nucl Med 2005;46:1753.
19. 18F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma. Ann Nucl Med 2008;22:83.
20. Enomoto K, Fukunaga T, Okazumi S, et al. Can fluorodeoxyglucose- positron emission tomography evaluate the functional differentiation of hepatocellular carcinoma? Kaku Igaku 1991;28:1353.
21. Cook GJR, Maisey MN, Fogelman I. Normal variants, artefacts, and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med 1999;26:1363.
22. Okazumi S, Isono K, Enomoto K, et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: Characterization of tumor and assessment of effect of treatment. J Nucl Med 1992;33:333.
23. Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995;36:1811.
24. Ho CL, Chen S, Yeung DW, et al. Dual-tracer PET=CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 2007;48:902.